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Abstract
Structural modifications affecting the efficacy of analogs of the endogenous opioid peptide
dynorphin (Dyn) A have focused on the N-terminal “message” sequence, based on the “message-
address” concept. To test the hypothesis that changes in the C-terminal “address” domain could
affect efficacy, modified amino acids and cyclic constraints were incorporated into this region of
the partial agonist [N-benzylTyr1]Dyn A-(1-11). Modifications in the C-terminal domain of [N-
benzylTyr1]Dyn A-(1-11)NH2 resulted in increased kappa opioid receptor (KOR) affinity for all
of the linear analogs, but did not affect the efficacy of these peptides at KOR. Cyclization between
positions 5 and 8 yielded [N-benzylTyr1,cyclo(D-Asp5,Dap8)]Dyn A-(1-11)NH2 (13) (Patkar et al.
J. Med. Chem. 2005, 48, 4500-4503) with high selectivity for KOR. In contrast to the linear
peptides, this peptide exhibits negligible efficacy in the AC assay and is a KOR antagonist. These
data are consistent with our hypothesis that appropriate modifications in the “address” domain of
Dyn A analogs may affect efficacy.
Introduction
Narcotic analgesics that target μ opioid receptors (MOR) have been used extensively in the
clinical management of pain,1 but their use is complicated by serious side effects.2 Thus
there has been considerable interest in the development of ligands for kappa opioid receptors
(KOR) as potential therapeutic agents for pain and other disorders.3 KOR agonists can
produce analgesia with less addiction liability and respiratory depression than MOR
agonists,4, 5 and compounds with KOR agonist activity are used clinically (e.g.
pentazocine). However, KOR agonists can also cause dysphoria in humans.6 In addition to
the centrally mediated analgesia, KOR agonists can produce antinociception through
peripheral KOR,7 and peripherally selective KOR agonists are in clinical trials as
analgesics.8 Moreover, KOR agonists also exhibit anti-inflammatory activity.9 Other
potentially useful therapeutic effects of KOR agonists include anticonvulsant and
neuroprotective effects and their ability to down-regulate HIV-1 expression in human
microglial and CD4 cells (see ref. 10 for a review). KOR antagonists, initially used only as
pharmacological tools, also have potential therapeutic uses in the treatment of
depression,11-13 anxiety,14, 15 and opiate and cocaine addiction.12, 16, 17 The KOR selective
peptide antagonist arodyn18 designed in our laboratory suppresses stress-induced
reinstatement of cocaine seeking behavior in mice,17 suggesting its potential use in the
development of peptide-based therapeutics for the treatment of cocaine addiction.
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The heptadecapeptide dynorphin (Dyn) A (Figure 1) is an endogenous agonist for KOR.19
Studies of Dyn A and its fragments by Chavkin and Goldstein led them to propose the
“message-address” concept in which the four N-terminal amino acids in Dyn A are the
“message” sequence responsible for opioid agonist activity and the C-terminal domain is the
“address” that enhances the affinity of this peptide for KOR.20 The entire C-terminal
sequence is not required for KOR interaction, however, and the first 11-13 residues of Dyn
A account for essentially all of the opioid activity of the longer peptide.20
We are interested in exploring the structural features of Dyn A that affect efficacy and result
in peptide antagonists for KOR. Structural modifications in the N-terminus of Dyn A can
alter efficacy as well as potency and selectivity. Alkylation of the N-terminus can influence
both KOR affinity and efficacy. While the N,N-diallylTyr1 analogs of [D-Pro10]Dyn A-
(1-11) and Dyn A-(1-13) exhibit antagonist activity at KOR and MOR21-23 (but with
decreased binding affinity and selectivity for KOR compared to the parent peptides without
the N-terminal modification), the monoalkylated derivatives have high KOR affinity and
selectivity.23, 24 The N-allyl- and N-cyclopropylmethyl (CPM) analogs are potent agonists
in the guinea pig ileum (GPI) assay, while the N-benzyl analog exhibits weak agonist
activity in the GPI assay23, 24 and is a partial agonist in the adenylyl cyclase (AC) assay
using cloned KOR expressed on Chinese hamster ovary (CHO) cells.25 Other modifications
in the N-terminal sequence of Dyn A-(1-11) analogs that result in antagonist activity at KOR
are Pro in the position 3,26 and the removal of the basic α-amine of Tyr1 in analogs such as
dynantin.27 Other analogs with antagonist activity, namely JVA-901,28 arodyn18 and
cycloN,5[Trp3,Trp4,Glu5]Dyn A-(1-11)NH2,29 prepared in our laboratory also lack a basic
N-terminus.
Reports in the literature examining modifications in the C-terminal or “address” sequence of
Dyn A suggest that in selected cases such modifications may affect the efficacy of these
analogs at KOR. While analogs of [Phe1]Dyn A-(1-11)NH2 with D-Ala8 and D-Pro10
substitutions retain similar KOR affinity (<50% difference), they exhibit large differences in
potency in the GPI30 (almost a 50-fold decrease for the D-Ala8 analog compared to the
parent peptide). Such discrepancies in affinity and potency suggest a possible role of the C-
terminus in the efficiency of receptor activation. A variety of cyclic analogs of Dyn A,
cyclized either with a disulfide or lactam linkage, have been prepared to restrict
conformational freedom and study possible bioactive conformations (see refs. 3, 31 for
reviews). Interestingly, some of these analogs also display discrepancies between KOR
affinity and potency in the GPI. Cyclic analogs with disulfide linkages between residues 5
and 11 ([5,11]), which may stabilize a reverse turn in the C-terminal region of Dyn A-
(1-13)NH2, were reported to possess high KOR affinity in brain homogenate but low
potency in the GPI assay, which the authors suggested could be due to different interactions
with central vs. peripheral KOR.32 Similarly, a series of lactam bridged [5,8] cyclic analogs
of Dyn A-(1-13)NH2 with varying ring sizes prepared in our laboratory exhibit much lower
potency in the GPI than anticipated based on their binding affinity.33 Also while the [5,8]
cyclic analogs exhibit similar binding affinities for KOR, they varied substantially in
potency in the GPI (IC50 = 530 - >5000 nM). Interestingly, a computational model suggests
a possible role for the hydrophobic residues Leu5 and Ile8 in the “address” sequence of Dyn
A-(1-10) in KOR activation.34 Molecular simulation of Dyn A-(1-10) bound to KOR
suggested that these two residues interact with hydrophobic residues in extracellular loop
(EL) 2 of KOR.34 Based on this model, it was proposed that these hydrophobic interactions
may play a role in the efficacy and/ or affinity of Dyn A for this receptor. In contrast, [6,9]
cyclic analogs exhibit similar KOR affinities and are potent agonists in the GPI (IC50 = 7-46
nM).33
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Based on these results we hypothesized that C-terminal residues and/or the conformation of
the C-terminal domain of Dyn A, while not a primary determinant, could affect the efficacy
of Dyn A analogs. To explore the possible roles of the C-terminus in efficacy, we introduced
a series of modifications into [N-benzylTyr1]Dyn A-(1-11) (Figure 2). This peptide was
chosen since [N-benzylTyr1,D-Pro10]Dyn A-(1-11) exhibits partial agonist activity in the
AC assay (71% relative to Dyn A-(1-13)NH2),25 and therefore we could readily detect
changes in efficacy. We anticipated that selected changes in the C-terminal domain of the
peptide [N-benzylTyr1]Dyn A-(1-11) could alter the efficacy of these analogs at KOR. Since
the basic residues in the C-terminal sequence of Dyn A were thought to be important in
KOR interaction,20 the modifications were mainly carried out in the non-basic residues in
the “address”. Based on the results with [Phe1]Dyn A-(1-11)NH2 analogs discussed above,
we chose D-Ala8 and D-Pro10 as modifications to incorporate into the C-terminal domain. In
order to retain the important Arg side chain but introduce a modification that could alter
peptide backbone conformation N-MeArg was also incorporated in position 7. Based on the
lactam bridged cyclic Dyn A analogs cyclo[D-Asp5,Dap8]- and cyclo[D-Asp6,Dap9]Dyn A-
(1-13)NH2 synthesized previously in our laboratory,33 we also examined cyclic constraints
between the 5th and 8th and the 6th and 9th positions in the C-terminal domain to evaluate
their effect on efficacy at KOR. These analogs were evaluated for their opioid receptor
affinity in radioligand binding assays and for opioid activity in the AC assay using cloned
KOR stably expressed on CHO cells.25 Among these, the [5,8] cyclic analog [N-
benzylTyr1,cyclo(D-Asp5,Dap8)]Dyn A-(1-11)NH2 (which we have named zyklophin)
exhibits negligible efficacy at KOR and acts an antagonist in the AC assay at KOR, as we
reported in an earlier communication.35 Here we describe the synthesis and report the
pharmacological profiles of the full series of C-terminally modified [N-benzylTyr1]Dyn A-
(1-11) analogs.
Chemistry
The peptides were synthesized using the Fmoc (9-fluorenylmethoxycarbonyl) solid phase
synthetic strategy (Scheme 1). N-Benzyltyrosine was synthesized separately in solution, and
then coupled to the peptide sequences. Selective monobenzylation of tyrosine tert-butyl ester
was carried out by reductive amination with benzaldehyde using sodium cyanoborohydride
in an acidic solution, followed by deprotection of the tert-butyl ester using trifluoroacetic
acid (TFA) to give N-benzyltyrosine. The Dyn A-(2-11) sequences were assembled on a
poly(ethylene glycol)-polystyrene (PEG-PS) resin containing the PAL [Peptide Amide
Linker, 5-(4-aminomethyl-3,5-dimethoxyphenoxy)valeric acid] linker for the amides and the
PAC [Peptide Acid Linker, (hydroxymethyl)phenoxyacetic acid] linker for the acid
derivatives 1, 3 and 4, using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N-methylmorpholine (NMM) in N,N-dimethylformamide
(DMF) to couple Fmoc-amino acids to the growing peptide chain.28 The side chain
protecting groups used were Pbf (2,2,4,6,7-pentamethyl-dihydrobenzofurane-5-sufonyl) and
Mtr (4-methoxy-2,3,6-trimethylbenzenesulfonyl) for the side chains of Arg and Nα-Me-Arg,
respectively, and Boc (t-butyloxycarbonyl) for Lys. The coupling of Fmoc-Arg(Pbf) at
position 6 to Nα-Me-Arg(Mtr) at position 7 and the coupling of N-benzyltyrosine to the
resin-bound Dyn A-(2-11) sequences were carried out using 7-azabenzotriazol-1-
yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP),36 1-hydroxy-7-
azabenzotriazole (HOAt) and N,N-diisopropylethylamine (DIEA) in DMF.
The cyclic peptides were assembled (Scheme 2) similar to the linear analogs except that
Fmoc-D-Asp(Pip) (Pip = 2-phenylisopropyl) and Fmoc-Dap(Mtt) (Dap = 2,3-
diaminopropionic acid and Mtt = 4-methyltrityl) were used in the positions involved in
cyclization. The hyperacid-labile Pip37 and Mtt38 protecting groups could be removed by
dilute (3%) TFA in the presence of the Boc and other tert-butyl type side chain protecting
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groups that require stronger acidic conditions for deprotection. The cyclizations between the
side-chain carboxylic acid of D-Asp and the side-chain free amine of Dap were carried out
using PyAOP, HOAt and DIEA in DMF. The cyclization between D-Asp in the position 6
and Dap in position 9, however, did not go to completion after 48 h, even using 6
equivalents of the coupling reagents, so the remaining unreacted amine was acetylated with
N-acetylimidazole and DIEA in DMF (Scheme 2). After cyclization, the remaining amino
acids were then coupled to complete the peptide sequences. For the synthesis of the
acetylated linear analogs 15 and 16, Fmoc-D-Asn(Trt) (Trt = trityl) and Fmoc-Dap(Mtt)
were used; following deprotection of the Mtt group with dilute TFA, the free amine of Dap
was acetylated using N-acetylimidazole in DMF.
The peptides were cleaved from the resin using either reagent B39 or modified reagent K40
(when N-MeArg(Mtr) was present in the peptide sequence). The crude peptides were
purified to ≥98% by preparative reversed phase HPLC and were analyzed for purity by
reversed phase HPLC and their molecular weights confirmed by ESI-MS (see Supporting
Information).
Results and discussion
The N-benzylTyr1 Dyn A-(1-11) analogs were evaluated for KOR, MOR, and delta opioid
receptor (DOR) affinity in radioligand binding assays (Table 1 and Figure 3) and for
efficacy in the adenylyl cyclase (AC) assay using cloned rat KOR stably expressed on CHO
cells (Figure 4). N-Benzylation of Dyn A-(1-11) and [D-Pro10]Dyn A-(1-11) resulted in
peptides 3 and 4, respectively, with Ki values of 15 nM for KOR using [3H]diprenorphine as
the radioligand. These results are comparable to the results we reported previously for 4 (Ki
= 18 nM).25 In contrast to other N-alkyl Dyn A analogs, the KOR affinity determined for the
[N-benzylTyr1,D-Pro10]Dyn A-(1-11) (4) depends on the radioligand used,25 and the 14-
fold decrease upon N-benzylation observed here was not found when the KOR affinity of 4
was determined using [3H]bremazocine in guinea pig cerebellum.23, 24 N-Benzylation of
Dyn A-(1-11) (1) and Dyn A-(1-11)NH2 (2) resulted in analogs 3 and 5, respectively, that
exhibit 2- to 3-fold increases in KOR vs. MOR selectivity and 3- to 5-fold increases in KOR
vs. DOR selectivity compared to 1 and 2 (Table 1) due to greater decreases in the affinities
for MOR and DOR compared to those for KOR.
We initially prepared both [N-benzylTyr1]Dyn A-(1-11) acid and amide derivatives (3 and
5, respectively) for comparison to [N-benzylTyr1,D-Pro10]Dyn A-(1-11) (4) which we
described previously.23-25 Compared to peptide 3, D-Pro in position 10 did not change the
KOR affinity for analog 4 but decreased affinity for DOR, thus improving KOR vs. DOR
selectivity. Interestingly, converting the C-terminal acid in analogs 3 and 4 to an amide
(peptides 5 and 8, respectively) increased KOR affinity slightly (2- to 3-fold). EL2 of KOR,
which has been implicated in Dyn A affinity and selectivity of KOR,34, 41 contains a unique
cluster of acidic residues that is not present in human and rodent MOR or DOR.42, 43 An
increase in the KOR affinity upon amidation may be due to the neutralization of unfavorable
interactions between the C-terminal acid with the acidic residues on the EL2 of KOR.
Conversion of the acid 3 to the amide 5 also increased selectivity for KOR over DOR 3-fold.
In contrast, the corresponding conversion of the acid in the D-Pro10 peptide 4 to give the
amide (analog 8) increased DOR affinity 6-fold, thus decreasing KOR vs. DOR selectivity.
In the linear analogs 6-12 modifications that could affect the C-terminal conformation were
well tolerated by KOR, with these analogs exhibiting 2- to 4-fold higher KOR affinity than
the parent peptide 5 (Table 1 and Figure 3). The introduction of a single modification in the
C-terminus of [N-benzylTyr1]Dyn A-(1-11)NH2 (analogs 6-8) resulted in similar small
increases (about 2-fold) in both KOR and MOR affinities regardless of the substitution
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introduced. The only notable difference in the affinities of these three analogs was the 3-fold
increase in DOR affinity as a result of incorporating D-Pro (analog 8). Introduction of an
additional modification in the C-terminus yielded analogs 9-11 with similar to slightly (up to
2-fold) higher KOR affinity than the monosubstituted analogs 6-8; analog 12 with all three
modifications exhibits KOR affinity similar to the monosubstituted derivatives 6-8 (Table 1
and Figure 3).
These modifications affected MOR and DOR affinities differently (Table 1). The MOR
affinities of the linear analogs 6-12 were similar to one another, regardless of the
substitutions, and generally about 2-fold higher than the parent peptide 5. Since these
changes in MOR affinity generally paralleled those for KOR, their selectivity for KOR over
MOR varied by only 2-fold among these analogs. The changes in DOR affinity, however,
were dependent on the type of substitution. While the N-MeArg7 and D-Ala8 modifications
improved selectivity for KOR over DOR slightly, D-Pro10 increased DOR affinity in the C-
terminal amide series, thereby reducing KOR vs. DOR selectivity. In peptides 9-12
containing substitutions in addition to D-Pro10, D-Ala8 but not N-MeArg7 alone decreased
DOR affinity and restored selectivity for KOR over DOR. Thus, analog 11 containing D-
Ala8 retained KOR vs. DOR selectivity, while the N-MeArg7 analog 10 exhibited higher
DOR affinity and therefore lower KOR selectivity. The addition of D-Ala8 to N-MeArg7
and D-Pro10, resulting in analog 12, restored the high KOR vs. DOR selectivity. Thus,
substitution of D-Ala in position 8 appears to be important for maintaining high selectivity
for KOR over DOR in these analogs.
In the cyclic peptides there was a marked difference in KOR affinity depending upon the
position of the cyclic constraint. As reported previously,35 the [5,8] cyclic peptide zyklophin
(13) shows approximately a 4-fold decrease in KOR affinity (Ki = 30 nM) compared to the
linear peptide 5. Cyclization between residues 6 and 9 (cyclic analog 14) led to a much
larger decrease in KOR affinity (Ki = 245 nM) compared to the linear analog 5. Zyklophin
and 14 both show drastic decreases in MOR and DOR affinities compared to the linear
peptide 5. The decreases in MOR and DOR affinities were larger as a result of the [5,8]
cyclization than due to the [6,9] cyclization. Thus the [5,8] cyclic analog zyklophin shows
much higher affinity for KOR and much lower affinities for MOR and DOR compared to the
[6,9] cyclic analog 14, resulting in much greater KOR selectivity (Table 1). The affinities for
all three opioid receptors for zyklophin (13) and analog 14, with N-benzylation of Tyr1, are
lower than those for the unbenzylated cyclo[D-Asp5,Dap8]- (17) and cyclo[D-
Asp6,Dap9]Dyn A-(1-13)NH2 (18).33 For the [5,8] cyclic derivative zyklophin, the KOR
affinity is 4-fold lower than that of 17 (Ki = 8 nM), but for the [6,9] cyclic derivative 14 the
KOR affinity is 100-fold lower than that of 18 (Ki = 2.6 nM), suggesting that the steric bulk
of the N-benzyl group may have shifted 14 in the KOR binding site relative to 18, leading to
the large decrease in affinity. Interestingly, zyklophin shows much higher KOR selectivity
over MOR compared to analog 17 (Ki ratio (KOR/MOR/DOR) = 1/9/412)33 that does not
possess the benzyl group on its N-terminal amine. Only a modest increase in selectivity for
KOR over MOR and DOR upon N-benzylation of Tyr1 was observed for the cyclic analog
cyclo[D-Asp2,Dap5]Dyn A-(1-11)NH2 (Ki = 3.8 nM, Ki ratio (KOR/MOR/DOR) = 1/5/56
for the N-benzylTyr1 derivative vs. Ki ratio = 1/1.1/11 for the unbenzylated analog).44
The linear analogs 15 and 16 were designed to evaluate the effect of the substitutions that
were used to carry out the cyclizations between positions 5 and 8 or 6 and 9, respectively, on
affinity and efficacy. To avoid effects due to the introduction of charged groups in the side
chains, Asn and Dap(Ac) were introduced into these positions. Substitution of Asn and
Dap(Ac) in positions 5 and 8, respectively, of 5 resulted in an 8-fold decrease in KOR
affinity and a much larger decrease in MOR affinity compared to analog 5. As reported
earlier,35 the [5,8] cyclization resulted in increases in KOR affinity and KOR vs. MOR
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selectivity compared to the linear analog 15. The linear peptide 16 with substitutions in
positions 6 and 9 exhibits extremely low affinity for all three opioid receptors (Table 1).
However, cyclization between these positions led to an 11-fold gain in KOR affinity for
analog 14 compared to 16, while the MOR affinity for 14 remained similar to the
corresponding linear analog 16. Thus the conformation induced by the cyclic constraint does
not appear to be responsible for the low KOR affinity of 14.
These analogs were evaluated for their efficacy in the AC assay using cloned rat KOR stably
expressed on CHO cells. At concentrations of 10 μM the linear peptides generally exhibit
partial to full agonist activity at KOR (Figure 4), similar to that originally reported for
peptide 3 (71% maximum inhibition of AC relative to Dyn A-(1-13)NH2).25 The linear
analogs with different C-terminal modifications (3-12) showed very similar maximum
inhibition of AC (70-90% relative to Dyn A-(1-13)NH2) regardless of the type of
substitution or number of substitutions. Thus, these changes in the C-terminal domain (N-
MeArg7, D-Ala8, D-Pro10 and/ or C-terminal amidation) of linear [N-benzylTyr1]Dyn A-
(1-11) analogs had little effect on the efficacy of the analogs at cloned KOR in the AC
assay. In contrast, the cyclic analog zyklophin (13) and the corresponding linear analog 15
show minimal efficacy in the AC assay, and as reported previously,35 zyklophin exhibits
antagonist activity (KB = 84 nM) at KOR in this assay.35 The linear analogs 14 and 16 were
not tested for efficacy due to their low KOR affinities.
Conclusions
Various C-terminal modified analogs of [N-benzylTyr1]Dyn A-(1-11) were synthesized to
evaluate the effect of these modifications on opioid receptor affinity and efficacy. The
effects on opioid receptor affinity varied depending upon the type of substitution and the
receptor type. Interestingly, introducing a C-terminal amide functional group appeared to
enhance KOR affinity slightly. While N-benzylation substantially decreased KOR affinity in
the linear analogs, incorporation of additional modifications in the C-terminus increased
KOR affinity by 2- to 4-fold in peptides 6-12 (Table 1 and Figure 3) such that the highest
affinity N-benzylated analog had relatively high KOR affinity (Ki = 2.2 nM for peptide 10).
Generally the effects on MOR affinity were similar, so that the selectivity of 6-12 for KOR
over MOR was within 2-fold that of 5. The effects of the substituents on DOR affinity were
more variable.
The most drastic changes in opioid receptor affinities occurred with the [5,8] and [6,9]
cyclic analogs. Modifications in positions 5 and 8 were tolerated by KOR but not by MOR
or DOR, leading to a large increase in KOR selectivity for zyklophin (13). The KOR affinity
of zyklophin is only 4-fold lower compared to the cyclic peptide 17 without an N-benzyl
group. In contrast, cyclization between positions 6 and 9 led to a very large decrease in KOR
affinity. Peptide 18 without an N-benzyl group exhibits nanomolar affinity for KOR (Ki =
2.6 nM), suggesting that N-terminal alkylation shifts the peptide in the binding site resulting
in the lower KOR affinities of 14 and 16.
There was a marked difference in the effects of the modifications in the linear analogs 3-12
vs. peptides 13 and 15 on efficacy in the AC assay. The linear analogs 3-12 all exhibit
similar efficacies regardless of the modifications in positions 7, 8 and/ or 10 that could affect
peptide conformation. In contrast, the modifications in positions 5 and 8 in peptides 13 and
15 eliminated efficacy at KOR. These results are consistent with our hypothesis that
appropriate modifications in the C-terminal domain can alter the efficacy of Dyn A analogs
at KOR. To further elucidate the role of the conformational constraint and stereochemistry
on efficacy, we are preparing a variety of analogs of zyklophin.
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Because of their target specificity and high potency, opioid peptides and their analogs could
be useful lead compounds for the development of therapeutic agents. The therapeutic use of
peptide-based drugs has been limited because of their low oral bioavailability. However,
alternative routes of administration such as inhalation45 are being explored that could
increase the acceptance of agents that aren’t taken orally. Structural modifications to the
endogenous peptides are necessary to impart sufficient metabolic stability for systemic
administration and for the development of clinically useful peptides. Incorporation of
unnatural amino acids along with conformational constraints, as are found in zyklophin,
provides the improved enzymatic stability needed for in vivo studies. Metabolically stable,
highly potent and KOR-selective peptide analogs can be used for a variety of central or
peripheral effects depending upon their penetration of the blood-brain barrier.10 Dyn A-
(1-11) analogs synthesized in our laboratory have shown blood-brain barrier penetration in
the in vitro bovine brain microvessel endothelial cell (BBMEC) model.46 KOR selective
peptide antagonists such as zyklophin can serve as lead compounds for the development of
potential treatments for opiate and cocaine addiction. Additional studies with this promising
lead peptide antagonist are ongoing in our laboratories.47
Experimental Section
Materials
The PAC-PEG-PS resin, PAL-PEG-PS resin, HOBt and DIEA were purchased from
Applied Biosystems (Foster City, CA). HBTU was purchased from EMD Biosciences (San
Diego, CA); HOAt and PyAOP were purchased from Applied Biosystems. Standard Fmoc-
protected amino acids were purchased from Applied Biosystems, EMD Biosciences and
Bachem Bioscience Inc. (King of Prussia, PA). Fmoc-Arg(Mtr), Fmoc-Dap(Mtt) and
TyrOtBu were purchased from EMD Biosciences. N-Benzyltyrosine was synthesized as
described in the Supporting Information. Piperidine, triisopropylsilane (TIS), and
trifluoroacetic acid (TFA) were purchased from Aldrich Chemical Co. (Milwaukee, WI). All
solvents (AcOH, MeCN (HPLC-grade), DMF, dichloromethane (DCM), MeOH (HPLC-
grade), and tetrahydrofuran (THF)) used for peptide synthesis or high performance liquid
chromatography (HPLC) analysis were obtained from either Burdick and Jackson, Inc.
(Muskegon, MI) or EM Sciences (Gibbstown, NJ). TFA for HPLC analysis was purchased
from Thermo-Fisher (Rockville, IL). Molecular weights of the compounds were determined
by electrospray ionization mass spectrometry (ESI-MS) using a Thermoquest LCQ mass
spectrometer (University of Maryland Baltimore) and/ or by fast atom bombardment mass
spectrometry (FAB-MS) on a Kratos MS50RF mass spectrometer (Oregon State University).
Purification and analysis of the peptides
The crude peptides were purified by preparative reversed phase HPLC (Rainin HPXL HPLC
system equipped with a Shimadzu SPD-10A detector) on a Vydac C18 column (10 μ, 300
Å, 21 × 250 mm) equipped with a Vydac guard cartridge. For purification a linear gradient
of 10-60% MeCN containing 0.1% TFA over 50 min, at a flow rate of 20 mL/min, was used.
The purification was monitored at 214 nm. The purity of the final peptides was verified on a
Vydac 218-TP column (5 μ, 300 Å, 4.6 × 250 mm) equipped with a Vydac guard cartridge
using a Beckman System Gold analytical HPLC, consisting of model 126 programmable
solvent module and model 168 diode array detector module. Two systems, a linear gradient
of 10-60% solvent B (solvent A, aqueous 0.1% TFA, and solvent B, MeCN containing 0.1%
TFA) over 50 min, at a flow rate of 1 mL/min (system 1), and a linear gradient of 5-80%
solvent B (solvent A, aqueous 0.1% TFA, and solvent B, MeOH containing 0.1% TFA) over
50 min, at a flow rate of 1.5 mL/min (system 2), were used for the analysis. The final purity
of all peptides by both analytical systems was generally >98 % (see Supporting
Information).
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Peptide synthesis: General procedure for peptides 1-12, 15 and 16
All of the peptides were synthesized by coupling a 4-fold excess of Fmoc-protected amino
acids (200 mM) on a Symphony Multiple Peptide Synthesizer (Rainin Inc.) using DMF as
the solvent or a 3-fold excess of Fmoc-protected amino acids using a 1:1 mixture of DCM
and DMF on a manual multiple peptide synthesizer (“CHOIR”) constructed in house.48
Peptides 2, 5-12, 15 and 16 were assembled on a high load PAL-PEG-PS resin (0.4 mmol/g,
200 mg) and peptides 13 and 14 were assembled on the low load PAL-PEG-PS resin (0.17
mmol/g, 200 mg). Peptides 1, 3 and 4 were assembled on an FmocLys(Boc)-
(hydroxymethyl)phenoxyacetic acid PEG-PS resin (PAC resin, 0.19 mmol/g, 200 mg). The
side chains of the amino acids Lys, Arg and N-MeArg were protected by Boc, Pbf and Mtr
groups, respectively. Following removal of the Fmoc protecting group using 20% piperidine
in DMF the amino acids were coupled using HBTU (equimolar to the amino acid) and
NMM (4-fold excess relative to the amino acid) as the coupling reagents for 2 h unless
otherwise noted. N-Benzyltyrosine (1.5-3 equiv) was coupled to the resin-bound peptides
using PyAOP, HOAt and DIEA (1:1:2 relative to the amino acid) in DMF (2-3 mL). Prior to
coupling, complete dissolution of N-benzyltyrosine was achieved by warming the solution
to 90 °C, followed by cooling to about 50-60 °C, and then adding PyAOP, HOAt and DIEA.
Completion of the coupling reactions was indicated by the qualitative ninhydrin test and/ or
chloranil test.49 During the synthesis of the Dyn A-(2-11) sequences, coupling of Fmoc-
Arg(Pbf)OH (6-fold excess) in position 6 to N-MeArg(Mtr) at position 7 of the Dyn A-
(7-11) segment was carried out manually using PyAOP, HOAt and DIEA (1:1:2 relative to
the amino acid) in a 1:1 mixture of DMF and DCM. The coupling was complete in 12-24 h,
as indicated by the chloranil test.
For peptides 15 and 16, after coupling Fmoc-Dap(Mtt) at position 8 or 9, respectively, the
Mtt group was selectively removed from the Dap side chain as follows: after swelling of the
peptide-resin for 5 min in DCM (5 mL), the resin was treated with a mixture of 3% TFA and
5% TIS in DCM (3 × 10 min, 5 mL each). The resin was subsequently washed first with
DCM and then with DMF (5 × 10 mL each). The free amine of the Dap side chain was then
acetylated using 1-acetylimidazole (10-fold excess) and DIEA (2-fold excess) in DMF:DCM
(3:1, 5 mL) for 1 h. The completion of the acylation was confirmed by the qualitative
ninhydrin test. FmocD-Asn(Trt) was incorporated in positions 5 or 6, respectively, for
peptides 15 and 16. After removal of the N-terminal Fmoc protecting group using 20%
piperidine in DMF (7 mL for 20 min), the rest of the amino acids were then coupled as
described in the general procedure to complete the assembly of the peptides.
The peptides were generally cleaved from the resin using Reagent B39 (88.5% TFA
containing 2.5% water, 2.5% phenol and 5% TIS as scavengers) except for peptides
containing N-MeArg. For these peptides containing the Mtr side chain protecting group on
N-MeArg, 5% thioanisole and 2.5% 1,2-ethanedithiol (EDT) in TFA40 were used along with
5% TIS and 2.5% phenol as scavengers. The peptides were filtered from the resin, and the
filtrates diluted with 10% acetic acid (about 10-15 mL) and extracted with diethyl ether (3 ×
20 mL). The ether extracts were back extracted with 10% acetic acid (20 mL). The
combined aqueous extracts were pooled and lyophilized to give the crude peptides.
Synthesis of compounds 13 and 14
Peptide 14 was synthesized using the same synthetic strategy as peptide 13 described
previously.35 The cyclic peptides were assembled similar to the linear analogs except that
Fmoc-D-Asp(Pip) and Fmoc-Dap(Mtt) were used in the positions involved in the
cyclizations. For 13, the amino acids from positions 5-11 and for 14, the amino acids from
positions 6-11 were coupled manually on the “CHOIR” as described above using HBTU and
NMM as the coupling reagents. The Pip and Mtt groups were then selectively deprotected
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with a mixture of 3% TFA and 5% TIS in DCM (3 × 10 min). The cyclization was carried
out by mixing the resin with a mixture of PyAOP, HOAt and DIEA (3:3:6 relative to the
resin substitution) dissolved in 1:1 DMF:DCM (4 mL) twice for a total of 24 h for 13 and
three times for a total of 48 h for 14. Any remaining unreacted free amine groups on Dap
were acetylated as described above, and the rest of the peptides were assembled as described
in the general procedure.
Pharmacological assays
Radioligand binding assays were performed as previously described33 using cloned rat KOR
and MOR and mouse DOR stably expressed on CHO cells. [3H]Diprenorphine (KD = 0.45
nM), [3H]DAMGO ([D-Ala2,MePhe4,glyol]enkephalin) (KD = 0.49 nM), and [3H]DPDPE
(cyclo[D-Pen2,D-Pen5]enkephalin) (KD = 1.76 nM) were used as radioligands in assays for
KOR, MOR and DOR, respectively. Results are mean ± SEM obtained from at least three
independent experiments.
Adenylyl cyclase assays were performed as previously described25 using cloned rat KOR
stably expressed on CHO cells. Peptides were evaluated at 10 μM compared to reference
agonist Dyn A-(1-13)NH2 (100 nM) to determine efficacy. Results are mean ± SEM
obtained from at least three independent experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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DOR delta opioid receptor
Dyn dynorphin
Fmoc 9-fluorenylmethoxycarbonyl
GPI guinea pig ileum
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOAt 1-hydroxy-7-azabenzotriazole
KOR kappa opioid receptor
MOR mu opioid receptor
Mtt 4-methyltrityl
PAC Peptide Acid Linker
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Dyn A-(1-11) and Its Analogs. Modifications in peptides 4-16 were made in the “address”
sequence (italicized in 3). Structural differences from peptide 5 are highlighted in bold in
subsequent analogs.
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KOR Affinities of [N-benzylTyr1]Dyn A-(1-11) Analogs
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Efficacies of [N-benzylTyr1]Dyn A-(1-11) Analogs as Inhibitors of Adenylyl cyclase (AC)
in CHO Cells Expressing KOR.a
a Percent AC inhibition relative to Dyn A-(1-13)NH2 (100%)
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Solid Phase Synthesis of Linear [N-benzylTyr1]Dyn A-(1-11) Analogs (1-12)
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Solid Phase Synthesis of Cyclic Peptide 14
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Table 1
Opioid Receptor Binding Affinities of Dyn A-(1-11) analogs
Peptide Ki (nM) ± SEM Ki Ratio
KOR MOR DOR KOR/MOR/DOR
1 Dyn A-(1-11) 1.11 ± 0.36 3.50 ± 0.42 8.18 ± 0.09 1/3/7
2 Dyn A-(1-11)NH2 0.57 ± 0.01 1.85 ± 0.52 6.18 ± 1.01 1/3/11
3 [N-benzylTyr1]Dyn A-(1-11)OH 14.8 ± 4.5 98.1 ± 9.8 345 ± 12 1/7/23
4 [N-benzylTyr1,D-Pro10]Dyn A-(1-11)OH 15.5 ± 1.0 159 ± 30 970 ± 131 1/10/63
5 [N-benzylTyr1]Dyn A-(1-11)NH2 8.17 ± 2.16 84.9 ± 16.5 474 ± 47 1/10/58
Analogs of [N-benzylTyr1]Dyn A-(1-11)NH2, 5
6 [Nα-MeArg7] 3.99 ± 1.09 49.9 ± 9.7 345 ± 31 1/13/86
7 [D-Ala8] 4.64 ± 0.91 51.2 ± 3.0 372 ± 25 1/11/80
8 [D-Pro10] 4.56 ± 0.42 45.1 ± 4.9 148 ± 5 1/10/32
9 [Nα-MeArg 7,D-Ala8] 3.11 ± 0.64 44.8 ± 7.3 458 ± 130 1/14/147
10 [Nα-MeArg 7,D-Pro10] 2.17 ± 0.22 36.5 ± 3.6 120 ± 24 1/17/55
11 [D-Ala8,D-Pro10] 3.10 ± 0.98 46.1 ± 8.6 337 ± 54 1/15/109
12 [Nα-MeArg 7,D-Ala8,D-Pro10] 4.40 ± 0.75 69.8 ± 0.7 665 ± 174 1/16/151
13a cyclo[D-Asp5,Dap8] (zyklophin) 30.3 ± 1.9 5880±1420 > 10,000 1/194/>330
14 cyclo[D-Asp6,Dap9] 245 ± 37 1190 ± 270 3663± 660 1/5/15
15a [D-Asn5,Dap(Ac)8] 66.9 ± 5.9 1660 ± 440 > 10,000 1/25/149
16 [D-Asn6,Dap(Ac)9] 2838 ± 302 1500 ± 310 4640± 340 2/1/3
a
From ref 35.
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